Table 2

Association between preceding sinusitis and incident rheumatic disease

Rheumatic diseaseAny sinusitis, n (%)Adjusted OR* for rheumatic disease by exposure
CasesControlsAny sinusitis (n=6916)Acute sinusitis (n=6432)Chronic sinusitis (n=6413)
Any rheumatic disease229 (13)503 (10)1.4 (1.2 to 1.7)1.4 (1.1 to 1.7)1.6 (1.3 to 1.9)
Rheumatoid arthritis97 (14)235 (11)1.3 (1.0 to 1.6)1.2 (0.9 to 1.7)1.3 (0.9 to 1.8)
 Seropositive61 (13)160 (12)1.2 (0.8 to 1.6)1.0 (0.7 to 1.5)1.3 (0.8 to 1.9)
 Seronegative36 (15)75 (11)1.5 (1.0 to 2.3)1.8 (1.1 to 3.1)1.3 (0.7 to 2.3)
Spondyloarthritis17 (15)37 (11)1.3 (0.7 to 2.5)1.5 (0.7 to 3.0)1.3 (0.6 to 2.9)
 Ankylosing spondylitis5 (23)8 (12)2.4 (0.6 to 9.2)2.2 (0.5 to 9.0)8.6 (0.9 to 79)
 Psoriatic arthritis12 (13)29 (11)1.1 (0.5 to 2.3)1.3 (0.6 to 3.0)0.8 (0.3 to 2.1)
Systemic autoimmune rheumatic disease37 (18)58 (10)2.2 (1.4 to 3.5)1.9 (1.0 to 3.5)2.6 (1.5 to 4.5)
 Antiphospholipid syndrome7 (27)3 (4)7.0 (1.8 to 27)N/A6.0 (1.5 to 24)
 Sjögren’s syndrome16 (22)24 (11)2.4 (1.1 to 5.3)2.4 (1.0 to 5.9)2.5 (0.9 to 6.7)
 Systemic lupus erythematosus3 (7)17 (13)0.5 (0.1 to 1.8)N/A0.9 (0.2 to 3.7)
 Systemic sclerosis4 (14)8 (9)1.7 (0.4 to 6.8)1.5 (0.3 to 7.2)1.7 (0.4 to 7.9)
Vasculitis78 (11)173 (8)1.4 (1.1 to 1.9)1.4 (1.0 to 2.1)1.6 (1.1 to 2.2)
 ANCA-associated vasculitis6 (16)13 (11)1.5 (0.5 to 4.4)1.6 (0.4 to 5.9)2.1 (0.6
to 6.9)
 Giant cell arteritis9 (11)21 (9)1.3 (0.5 to 3.3)1.3 (0.4 to 4.5)1.3 (0.4 to 4.5)
 Polymyalgia rheumatica63 (10)139 (8)1.4 (1.0 to 2.0)1.4 (0.9 to 2.1)1.5 (1.1 to 2.2)
  • *Reference group was individuals with no sinusitis codes prior to index date. Adjusting for age, sex, electronic health record history, race and ethnicity, body mass index, smoking status. Bold values were statistically significant.

  • †Unadjusted conditional logistic regression due to small sample size.

  • ANCA, antineutrophil cytoplasmic antibody; N/A, not applicable due to insufficient exposures.